Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients.

We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecamylamine will be effective in reducing both alcohol consumption and smoking in a subset of alcoholics who also smoke.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Ethanol; Mecamylamine

Criteria

Inclusion Criteria:

• individuals with DSM-IV diagnosis of alcohol dependence

• smokers and non-smokers

• patients who do not require psychotropic medication for the management of their psychiatric symptoms

• individuals with a history of substance dependence (other than alcohol and tobacco) but have not met criteria for substance dependence in the past 30 days

• women with acceptable method of contraception

Exclusion Criteria:

• pregnant women

• medications thought to influence drinking behavior including: acamprosate, disulfiram, naltrexone and ondansetron

• underlying medical conditions

• history of glaucoma, prostatic hypertrophy, urethral obstruction, cerebral arteriosclerosis, pyloric stenosis, or a history of hypersensitivity to mecamylamine

• DSM-IV diagnosis of bipolar disorder, schizophrenia, and schizophrenia-type disorders

• unstable medical conditions

• patients who require psychotropic medication for the management of an active psychiatric disorder

• patients on pharmacological treatment for alcohol and/or nicotine dependence